
    
      After primary diagnosis eligible patients receive 2 to 3 courses of CHOEP-21 with formal
      restaging after course 2. Patients with CR, PR or no change proceed to allo-HSCT. Donor
      selection: Matched sibling donor(MSD) is the first choice. An unrelated donor or
      haploidentical family donor search is performed in patients without sibling donor. The
      primary end point was 1 year progression-free survival. The secondary end points were
      complete commission rate, transplant-related mortality, overall survival, relapse rate and
      graft-versus-host disease (GVHD) . Following time is 2 years
    
  